US Patent Issued to ARCUTIS BIOTHERAPEUTICS on Aug. 19 for "Method for reducing side effects from administration of phosphodiesterase-4 inhibitors" (Colorado Inventor)

ALEXANDRIA, Va., Aug. 20 -- United States Patent no. 12,390,453, issued on Aug. 19, was assigned to ARCUTIS BIOTHERAPEUTICS INC. (Westlake Village, Calif.).

"Method for reducing side effects from administration of phosphodiesterase-4 inhibitors" was invented by David W. Osborne (Fort Collins, Colo.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in b...